BeOne Medicines drug Beqalzi has accelerated FDA approval for treating relapsed or refractory mantle cell lymphoma, a type of blood cancer. The regulatory nod opens the door to potentially compete against Venclexta, a blockbuster cancer drug marketed by AbbVie and Roche. The post FDA Approval Gives BeOne Medicines a New Challenger to AbbVie, Roche Cancer…
Matthias Kleinz, executive vice president and head of translational sciences investments at UPMC Enterprises, explained why biopharma companies cannot ignore China anymore. The post UPMC Enteprises’ Biopharma Lead: We are At a Tipping Point When it Comes to China appeared first on MedCity News.
For five years straight, patients responding to the State of Patient Access survey have ranked “seeing a doctor quickly” as a top priority. Unfortunately, 94% of patients are still waiting more than two weeks for an appointment. Too many find themselves stuck in scheduling dead-ends, with unanswered calls, endless hold times and limited options when…
This brief analyzes federal transparency data released by the Centers for Medicare and Medicaid Services (CMS) on claims denials and appeals for non-group qualified health plans (QHPs) offered on HealthCare.gov in 2023. It finds that HealthCare.gov insurers denied nearly one out of every five claims (19%) submitted for in-network services. Information about the reasons for…
Kim Beckham, agente de seguros en Victoria, Texas, había visto a sus amigos sufrir tanto por la culebrilla (shingles) que quería recibir la primera vacuna aprobada contra esta infección tan pronto como estuviera disponible, incluso si tenía que pagarla de su bolsillo. Su médico y varias farmacias le dijeron que no podían administrarle la vacuna…
Herself Health and Blue Cross and Blue Shield of Minnesota have shifted away from a fee-for-service arrangement to a value-based arrangement. The post Blue Cross and Blue Shield of Minnesota, Herself Health Shift To VBC Contract appeared first on MedCity News.
GLP-1s have real value, but not all people respond to them the same way. The real question isn’t just what these drugs cost, but who they’re working for — and our healthcare system doesn’t have a reliable way to reconcile the two. The post America Is Betting Big On GLP-1s. It Doesn’t Have To Be…
The vast majority of healthcare organizations have spotted a cyberattack and suffered financial consequences as a result in the past 12 months, according to new research. A separate report also found that overall cyberattacks on healthcare organizations have risen by 32% year-over-year. The post Cybersecurity Threats Continue to Rise for Healthcare Organizations, Research Shows appeared…
We should use AI to develop recommendations for breast cancer screening protocols based on quantified risk, factoring in family history, ethnicity, genetics, and density, et al. – and then support the use of powerful new imaging AI technologies for those cases that demand a deeper look. The post Navigating the Breast Cancer Screening Debate: The…
Perfuse Therapeutics brings Bayer an eye drug administered via an implant that controls the release of the therapy. This program is in mid-stage clinical development for glaucoma and diabetic retinopathy. The post Bayer Sees Opportunity With $300M Acquisition of Eye Drug Biotech appeared first on MedCity News.